| Hazard Information | Back Directory | [Description]
Poloxipan is a potent and pan-specific PLK1 inhibitor. In vitro, Poloxipan has IC50 3.2 uM (Plk1); 1.7 uM (Plk2); and 3 uM (Plk3). Poloxipan showed minor inhibition over FHA dommain of Chk2, S2 domian of STAT1, STAT5b, Lck, etc. | [Uses]
Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus called the Polo-box domain (PBD) found in kinases. The IC50 values for Poloxipan against the PBDs of PLK-1/2/3 are 3.2 μM, 1.7 μM, and 3.0 μM, respectively. Poloxipan also inhibits other phospho-tyrosine binding domains, such as the forkhead-associated (FHA) domain of CHK-2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the phospho-tyrosine binding domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase's SH2 domain. Poloxipan can be used in cancer research[1]. | [References]
[1] Kumar S, et al. PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis. Biomed Res Int. 2015;2015:705745. DOI:10.1155/2015/705745 |
|
| Company Name: |
OTAVA chemicals
|
| Tel: |
416 305 9979 (Canada) |
| Website: |
www.otavachemicals.com |
|